JNK inhibitors as anti-inflammatory and neuroprotective agents

Future Medicinal Chemistry

Volumn 5, Issue 5, 2013, Pages 539-551

  Graczyk, Piotr P ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; BENTAMAPIMOD; BI 90H9; ER 358063; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TANZISERTIB; UNCLASSIFIED DRUG; XG 102;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BINDING SITE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG SELECTIVITY; EXCITOTOXICITY; HUMAN; IC 50; LIVER INJURY; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THERAPY DELAY; TRANSIENT ISCHEMIC ATTACK; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS;

EID: 84876139608     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.34     Document Type: Review

References (114)

1. Yamasaki T, Kawasaki H, Nishina H. Diverse roles of JNK and MKK pathways in the brain. J. Signal Transduct. doi:10.1155/2012/459265 (2012) (Epub ahead of print).
2. Haeusgen W, Boehm R, Zhao Y, Herdegen T, Waetzig V. Specific activities of individual c-Jun N-terminal kinases in the brain. Neuroscience 161(4), 951-959 (2009).
3. Vallerie SN, Hotamisligil GS. The role of JNK proteins in metabolism. Sci. Transl. Med. 2(60), 60rv5 (2010).
4. Belgardt BF, Mauer J, Brüning JC. Novel roles for JNK1 in metabolism. Aging (Albany NY) 2(9), 621-626 (2010).
5. Sabio G, Davis RJ. cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance. Trends Biochem. Sci. 35(9), 490-496 (2010).
6. Huang G, Shi LZ, Chi H. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine 48(3), 161-169 (2009).
7. Morishima Y, Gotoh Y, Zieg J et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21(19), 7551-7560 (2001).
8. Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J. Neurosci. 25(23), 5533-5543 (2005).
9. Antoniou X, Falconi M, Di Marino D, Borsello T. JNK3 as a therapeutic target for neurodegenerative diseases. J. Alzheimers Dis. 24(4), 633-642 (2011).
10. Tare M, Modi RM, Nainaparampil JJ et al. Activation of JNK signaling mediates amyloid-b-dependent cell death. PLoS ONE 6(9), e24361 (2011).
11. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr. Drug Targets CNS Neurol. Disord. 4(1), 63-67 (2005).
12. Silva RM, Kuan CY, Rakic P, Burke RE. Mixed lineage kinase-c-Jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov. Disord. 20(6), 653-664 (2005).
13. Bonny C, Borsello T, Zine A. Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases. Rev. Neurosci. 16(1), 57-67 (2005).
14. Pan J, Wang G, Yang HQ et al. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways. Mol. Pharmacol. 72(6), 1607-1618 (2007).
15. Mehan S, Meena H, Sharma D, Sankhla R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J. Mol. Neurosci. 43(3), 376-390 (2011).
16. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology 47(4), 409-414 (2008).
17. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22(4), 667-676 (1999).
18. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech. Dev. 89(1-2), 115-124 (1999).
19. Wang LW, Tu YF, Huang CC, Ho CJ. JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. J. Neuroinflammation 9, 175 (2012).
20. Huang P, Han J, Hui L. MAPK signaling in inflammation-associated cancer development. Protein Cell 1(3), 218-226 (2010).
21. Cellurale C, Sabio G, Kennedy N J et al. Requirement of c-Jun NH2-terminal kinase for ras-initiated tumor formation. Mol. Cell. Biol. 31(7), 1565-1576 (2011).
22. Cellurale C, Girnius N, Jiang F et al. Role of JNK in mammary gland development and breast cancer. Cancer Res. 72(2), 472-481 (2012).
23. Thornton C, Rousset CI, Kichev A et al. Molecular mechanisms of neonatal brain injury. Neurol. Res. Int. 2012, 506320 (2012).
24. Johnson GL, Nakamura K. The c-Jun kinase/ stress-activated pathway: regulation, function and role in human disease. Biochim. Biophys. Acta 1773(8), 1341-1348 (2007).
25. Brecht S, Kirchhof R, Chromik A et al. Specific pathophysiological functions of JNK isoforms in the brain. Eur. J. Neurosci. 21(2), 363-377 (2005).
26. Kuan CY, Whitmarsh AJ, Yang DD et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl Acad. Sci. USA 100(25), 15184-15189 (2003).
27. Yang DD, Kuan CY, Whitmarsh AJ et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389(6653), 865-870 (1997).
28. Hunot S, Vila M, Teismann P et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 665-670 (2004).
29. Tran EH, Azuma YT, Chen M, Weston C, Davis RJ, Flavell RA. Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain. Proc. Natl Acad. Sci. USA 103(36), 13451-13456 (2006).
30. Nicolson K, Freland S, Weir C, Delahunt B, Flavell RA, Bäckström BT. Induction of experimental autoimmune encephalomyelitis in the absence of c-Jun N-terminal kinase 2. Int. Immunol. 14(8), 849-856 (2002).
31. Yoshimura K, Ueno M, Lee S et al. c-Jun N-terminal kinase induces axonal degeneration and limits motor recovery after spinal cord injury in mice. Neurosci. Res. 71(3), 266-277 (2011).
32. Han Z, Chang L, Yamanishi Y, Karin M, Firestein GS. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 46, 818-823 (2002).
33. Guma M, Ronacher LM, Firestein GS, Karin M, Corr M. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum. 63(6), 1603-1612 (2011).
34. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 420(6913), 333-336 (2002).
35. Jaeschke A, Rincón M, Doran B et al. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of Type I diabetes. Proc. Natl Acad. Sci. USA 102(19), 6931-6935 (2005).
36. Ijaz A, Tejada T, Catanuto P et al. Inhibition of c-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int. 75(4), 381-388 (2009).
37. Wei J, Wang W, Chopra I et al. c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction. J. Biol. Chem. 286(16), 13995-14006 (2011).
38. Osto E, Matter CM, Kouroedov A et al. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation 118(20), 2073-2080 (2008).
39. Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43(1), 163-172 (2006).
40. Kodama Y, Kisseleva T, Iwaisako K et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137(4), 1467-1477 e5 (2009).
41. Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Czaja MJ. Tumor necrosis factor-induced toxic liver injury results from JNK2- dependent activation of caspase-8 and the mitochondrial death pathway. J. Biol. Chem. 281(22), 15258-15267 (2006).
42. Van der Velden J, Janssen-Heininger YM, Mandalapu S, Scheller EV, Kolls JK, Alcorn JF. Differential requirement for c-Jun N-terminal kinase 1 in lung inflammation and host defense. PLoS ONE 7(4), e34638 (2012).
43. She QB, Chen N, Bode AM, Flavell RA, Dong Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol- 13-acetate. Cancer Res. 62, 1343-1348 (2002).
44. Chen N, Nomura M, She QB et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 61(10), 3908-3912 (2001).
45. Chen P, O'Neal JF, Ebelt ND et al. Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS ONE 5(5), e10443 (2010).
46. Hübner A, Mulholland DJ, Standen CL et al. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc. Natl Acad. Sci. USA 109(30), 12046-12051 (2012).
47. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118(12), 3943-3953 (2008).
48. Björkblom B, Vainio JC, Hongisto V, Herdegen T, Courtney MJ, Coffey ET. All JNKs can kill, but nuclear localization is critical for neuronal death. J. Biol. Chem. 283(28), 19704-19713 (2008).
49. Abdelli S, Bonny C. JNK3 maintains expression of the insulin receptor substrate 2 (IRS2) in insulin-secreting cells: functional consequences for insulin signaling. PLoS ONE 7(5), e35997 (2012).
50. Bogoyevitch MA. The isoform-specific functions of the c-Jun N-terminal kinases (JNKs): differences revealed by gene targeting. Bioessays 28(9), 923-934 (2006).
51. Haeusgen W, Herdegen T, Waetzig V. The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur. J. Cell Biol. 90(6-7), 536-544 (2011).
52. Siddiqui MA, Reddy PA. Small molecule JNK (c-Jun N-terminal kinase) inhibitors. J. Med. Chem. 53(8), 3005-3012 (2010).
53. Bogoyevitch MA, Arthur PG. Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim. Biophys. Acta 1784, 76-93 (2008).
54. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim. Biophys. Acta 1804(3), 463-475 (2010).
55. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov. Today 9, 932-939 (2004).
56. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50(1), 77-82 (2001).
57. Bennett BL, Sasaki DT, Murray BW et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA 98(24), 13681-13686 (2001).
58. Han Z, Boyle DL, Chang L et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108(1), 73-81 (2001).
59. Benakis C, Bonny C, Hirt L. JNK inhibition and inflammation after cerebral ischemia. Brain Behav. Immun. 24(5), 800-811 (2010).
60. Vaslin A, Naegele-Tollardo S, Puyal J, Clarke PG. Excitotoxicity-induced endocytosis mediates neuroprotection by TAT-peptide-linked JNK inhibitor. J. Neurochem. 119(6), 1243-1252 (2011).
61. Spigolon G, Veronesi C, Bonny C, Vercelli A. c-Jun N-terminal kinase signaling pathway in excitotoxic cell death following kainic acid-induced status epilepticus. Eur. J. Neurosci. 31(7), 1261-1272 (2010).
62. Zhao Y, Spigolon G, Bonny C, Culman J, Vercelli A, Herdegen T. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. Mol. Cell. Neurosci. 49(3), 300-310 (2012).
63. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672 (2007).
64. Tran HT, Sanchez L, Brody DL. Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice. J. Neuropathol. Exp. Neurol. 71(2), 116-129 (2012).
65. Reinecke K, Eminel S, Dierck F et al. The JNK inhibitor XG-102 protects against TNBS-induced colitis. PLoS ONE 7(3), e30985 (2012).
66. Kaoud TS, Mitra S, Lee S et al. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem. Biol. 6(6), 658-666 (2011).
67. Guan Z, Kim JH, Lomvardas S et al. p38 MAP kinase mediates both short-term and long-term synaptic depression in aplysia. J. Neurosci. 23(19), 7317-7325 (2003).
68. Borsello T, Clarke PG, Hirt L et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9(9), 1180-1186 (2003).
69. Guan QH, Pei DS, Zhang QG, Hao ZB, Xu TL, Zhang GY. The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways. Brain Res. 1035(1), 51-59 (2005).
70. Murata Y, Fujiwara N, Seo JH et al. Delayed inhibition of c-Jun N-terminal kinase worsens outcomes after focal cerebral ischemia. J. Neurosci. 32(24), 8112-8115 (2012).
71. Reinhart PH, Kaltenbach LS, Essrich C et al. Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay. Neurobiol. Dis. 43(1), 248-256 (2011).
72. Chen X, Wu J, Hua D et al. The c-Jun N-terminal kinase inhibitor SP600125 is neuroprotective in amygdala kindled rats. Brain Res. 1357, 104-114 (2010).
73. Braithwaite SP, Schmid RS, He DN et al. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease. Neurobiol. Dis. 39 (3), 311-317 (2010).
74. Liedhegner EA, Steller KM, Mieyal JJ. Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease. Chem. Res. Toxicol. 24(10), 1644-1652 (2011).
75. Sun H, Wang Y, Pang IH et al. Protective effect of a JNK inhibitor against retinal ganglion cell loss induced by acute moderate ocular hypertension. Mol. Vis. 17, 864-875 (2011).
76. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204 (2003).
77. Tanemura S, Momose H, Shimizu N et al. Blockage by SP600125 of Fce receptor-induced degranulation and cytokine gene expression in mast cells is mediated through inhibition of phosphatidylinositol 3-kinase signaling pathway. J. Biochem. 145, 345-354 (2009).
78. Rincón M, Whitmarsh A, Yang DD et al. The JNK pathway regulates the in vivo deletion of immature CD4(+)CD8(+) thymocytes. J. Exp. Med. 188, 1817-1830 (1998).
79. Yang DD, Conze D, Whitmarsh AJ et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9, 575-585 (1998).
80. Conze D, Krahl T, Kennedy N et al. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J. Exp. Med. 195, 811-823 (2002).
81. Tabata A, Morikawa M, Miyajima M et al. Suppression of alloreactivity and allograft rejection by SP600125, a small molecule inhibitor of c-Jun N-terminal kinase. Transplantation 83, 1358 (2007).
82. Lassmann H. What drives disease in multiple sclerosis: inflammation or neurodegeneration? Clin. Exp. Neuroimmunol. 1, 2-11 (2010).
83. Greenberg B. Current therapies and clinical trials. Adv. Stud. Med. 9(2), 42-47 (2009).
84. Lingor P, Koch JC, Tönges L, Bähr M. Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res. 349(1), 289-311 (2012).
85. Schulze-Topphoff U, Shetty A, Varrin-Doyer M et al. Laquinimod, a quinoline-3- carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 7(3), e33797 (2012).
86. Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 123(1), 53-61 (2011).
87. Serge H. Designing heterocyclic selective kinase inhibitors: from concept to new drug candidates. ARKIVOC 7, 496-508 (2006).
88. Ferrandi C, Richard F, Tavano P et al. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult. Scler. 17(1), 43-56 (2011).
89. Sheridan C. PregLem in-licenses Merck Serona's jun kinase inhibitor. BioWorld International, 18 August (2010).
90. Barden L, Bhatia G, Castro L et al. Brain penetrant Jun kinase inhibitors for the treatment of multiple sclerosis. MEDI-354 Abstracts of Papers. Presented at: 243rd ACS National Meeting and Exposition. San Diego, CA, USA, 25-29 March 2012.
91. Graczyk P. Gini Coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 50(23), 5773-5779 (2007).
92. Amor S, Smith PA, Hart B, Baker D. Biozzi mice: of mice and human neurological diseases. J. Neuroimmunol. 165(1-2), 1-10 (2005).
93. Neitz RJ, Konradi AW, Sham HL et al. Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement. Bioorg. Med. Chem. Lett. 21(12), 3726-3729 (2011).
94. Bowers S, Truong AP, Neitz RJ et al. Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor. Bioorg. Med. Chem. Lett. 21(6), 1838-1843 (2011).
95. Bowers S, Truong AP, Jeffrey Neitz R et al. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. Bioorg. Med. Chem. Lett. 21(18), 5521-5527 (2011).
96. De SK, Chen V, Stebbins JL et al. Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. 18(2), 590-596 (2010).
97. De SK, Barile E, Chen V et al. Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase. Bioorg. Med. Chem. 19(8), 2582-2588 (2011).
98. Hom RK, Bowers S, Sealy JM et al. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg. Med. Chem. Lett. 20(24), 7303-7307 (2010).
99. Lisnock J, Griffin P, Calaycay J et al. Activation of JNK3a1 Requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3a1. Biochemistry 39, 3141-3148 (2000).
100. Coffey ET, Smiciene G, Hongisto V et al. c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci. 22(11), 4335-4345 (2002).
101. Bain J, Plater L, Elliott M et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408(3), 297-315 (2007).
102. Sugino T, Nozaki K, Takagi Y et al. Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus, J. Neurosci. 20, 4506-4514 (2000).
103. Probst GD, Bowers S, Sealy JM et al. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg. Med. Chem. Lett. 21(1), 315-319 (2011).
104. Plantevin Krenitsky V, Nadolny L, Delgado M et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg. Med. Chem. Lett. 22(3), 1433-1438 (2012).
105. Krenitsky VP, Delgado M, Nadolny L et al. Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg. Med. Chem. Lett. 22(3), 1427-1432 (2012).
106. Stebbins JL, De SK, Pavlickova P et al. Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. J. Med. Chem. 54(18), 6206-6214 (2011).
107. Kamenecka T, Jiang R, Song X et al. Synthesis, biological evaluation, x-ray structure, and pharmacokinetics of aminopyrimidine c-Jun-N-terminal kinase (JNK) inhibitors. J. Med. Chem. 53(1), 419- 431 (2010).
108. He Y, Kamenecka TM, Shin Y et al. Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-Jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett. 21(6), 1719-1723 (2011).
109. Noël R, Shin Y, Song X et al. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett. 21(9), 2732-2735 (2011).
110. Song X, Chen W, Lin L et al. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett. 21(23), 7072-7075 (2011).
111. Deisseroth A, Kaminskas E, Grillo J et al. US food and drug administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin. Cancer Res. 18(12), 3212-3217 (2012).
112. Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol. 8(4), 319-331 (2012).
113. Ostermeier E, Roll P, Tony HP. Janus kinase inhibitors. Z. Rheumatology 71(6), 473-478 (2012).
114. Gedeon Richter. Research and development. www.preglem.com/en/research- and-development (Accessed 27 January 2013